graduate image

E-brochureOphthalmology (Pathogenesis of ocular neovascular diseases)

Master's Program Human Sciences, Graduate School of Medicine
Doctor's Program Medical Science Division, Department of Medical Science, Graduate School of Medicine, Science and Technology

Staff List

Professor MURATA Toshinori
Associate Professor HIRANO Takao
Senior Assistant Professor KUROKAWA Toru,
Assistant Professor TOKIMITSU Motoharu, YOSHIDA Noriko, KAKIHARA Shinji, SHU Sayuri

Contact

E-mail : murata(at)shinshu-u.ac.jp
※ Change (at) to @ when you send an e-mail.

Summary of Activity

We are conducting both basic and clinical research. There is a substance in the body called adrenomedullin that dilates blood vessels, and recently it has been pointed out that adrenomedullin may improve retinal diseases. We are studying the effects of adrenomedullin on the eye. At the same time, we are analyzing data obtained in clinical settings to generate new findings.

Research Subject

  • ・Study on the influence of adrenomedullin and its family peptides on the mouse retinal diseases
  • ・Study of ophthalmic imaging and treatment outcomes in the clinical setting

Outlook for Research

With the aging of society, eye diseases such as diabetic retinopathy and age-related macular degeneration are expected to increase. There are already several treatments for these diseases, but in the future, adrenomedullin may become one of the treatments!

Major Publications

1. Hirano T, Toriyama Y, Takamura Y, Sugimoto M, Nagaoka T, Sugiura Y, Okamoto F, Saito M, Noda K, Yoshida S, Ishibazawa A, Sawada O, Murata T. Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema. Sci Rep. 2021 Feb 24;11(1):4488.

2. Murata T, Kondo M, Inoue M, Nakao S, Osaka R, Shiragami C, Sogawa K, Mochizuki A, Shiraga R, Ohashi Y, Kaneko T, Chandrasekhar C, Tsujikawa A, Kamei M. The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients. Sci Rep. 2021 Jan 12;11(1):551.

3. Kakihara S, Hirano T, Matsuda Y, Takano D, Imai A, Miyahara T, Murata T. Deposits on Retinal Surface Seen on OCT in Ocular Amyloidosis. Ophthalmol Retina. 2021 Oct;5(10):1005-1008.

4. Tanaka M, Kakihara S, Hirabayashi K, Imai A, Toriyama Y, Iesato Y, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, Tanaka M, Cui N, Wei Y, Zhao Y, Aruga K, Yamauchi A, Murata T, Shindo T. Adrenomedullin-Receptor Activity-Modifying Protein 2 System Ameliorates Subretinal Fibrosis by Suppressing Epithelial-Mesenchymal Transition in Age-Related Macular Degeneration. Am J Pathol. 2021 Apr;191(4):652-668.

5. Kakihara S, Hirano T, Imai A, Miyahara T, Murata T. Small gauge vitrectomy for vitreous amyloidosis and subsequent management of secondary glaucoma in patients with hereditary transthyretin amyloidosis. Sci Rep. 2020 Mar 27;10(1):5574.

6. Hirabayashi K, Kakihara S, Tanaka M, Shindo T, Murata T. Investigation of the therapeutic mechanism of subthreshold micropulse laser irradiation in retina. Graefes Arch Clin Exp Ophthalmol. 2020 May;258(5):1039-1047.

7. Hirano T, Hoshiyama K, Hirabayashi K, Wakabayashi M, Toriyama Y, Tokimitsu M, Murata T. Vitreoretinal Interface Slab in OCT Angiography for Detecting Diabetic Retinal Neovascularization. Ophthalmol Retina. 2020 Jun;4(6):588-594.

8. Hirabayashi K, Tanaka M, Imai A, Toriyama Y, Iesato Y, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, Tanaka M, Dai K, Cui N, Wei Y, Nakamura K, Iida S, Matsui S, Yamauchi A, Murata T, Shindo T. Development of a Novel Model of Central Retinal Vascular Occlusion and the Therapeutic Potential of the Adrenomedullin-Receptor Activity-Modifying Protein 2 System. Am J Pathol. 2019 Feb;189(2):449-466.

9. Hirano T, Kitahara J, Toriyama Y, Kasamatsu H, Murata T, Sadda S. Quantifying vascular density and morphology using different swept-source optical coherence tomography angiographic scan patterns in diabetic retinopathy. Br J Ophthalmol. 2019 Feb;103(2):216-221.

10. Hirano T, Toriyama Y, Iesato Y, Imai A, Murata T. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Retina. 2018 Sep;38(9):1801-1808.

GRADUATE
  • Join us in Shinshu Med. School, NAGANO
  • Short-term Elective Training for Foreign Medical Students
  • Shinshu University
  • GET Global Education Center
  • List of Universities with Partnership Agreements